In this issue of Blood, Sehgal et al report on the clinical and pharmacodynamic analysis of pomalidomide dosing strategies in multiple myeloma (MM) and their impact on immune activation and cereblon targets. The particular novelty of this study lies in the direct correlation of immune effects triggered by pomalidomide with clinical responses in MM patients. Results of this study will stimulate many additional studies. The addition of pomalidomide to the armamentarium of anti-MM agents has significantly improved the outcome in MM patients, even in those resistant against bortezomib and/or lenalidomide. The present study considerably extends our understanding of in vivo anti-MM effects of pomalidomide. It demonstrates that pomalidomide triggers strong and rapid immunomodulatory effects involving both innate and adaptive immunity, even in heavily pretreated MM, and that these effects correlate with clinical responses. Most importantly, Sehgal et al provide the basis for new avenues of future investigation. Specifically, joint efforts should aim to further optimize pomalidomide/dexamethasone dosing schedules, to identify reliable biomarkers for IMiD/pomalidomide responders, and to rationally enhance immune effects of pomalidomide by combination therapies with immune checkpoint inhibitors in particular, to further improve MM patient outcome.
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In this issue of Blood, Prasad et al provide evidence for a new role for the B-lineage transcriptional regulator early B-cell factor 1 (Ebf1) during early B-cell development and B-cell acute lymphoblastic leukemia (B-ALL). 2 They also preserve B-lineage fidelity by suppressing expression of signaling and transcription factors that promote alternate fates latent in these early precursors. The outcome of this complex transcriptional process is the generation of the humoral arm of the immune system through the production of a diverse repertoire of properly selected mature B cells capable of antibody production on antigenic challenge. Loss-of-function mutations in EBF1 and other B-lineage transcriptional regulators, such as PAX5, are associated with B-ALL in humans. [3] [4] [5] Notably, the leukemogenic effect of these mutations manifests at the heterozygous level with differentiation only partly affected, suggesting that other dose-dependent functions of these factors in B-cell precursors are contributing to the disease state.
It might seem surprising that impaired function of EBF1 would lead to B-ALL because genetic studies in mice have shown that Ebf1 supports proliferation of B-cell precursors and mature B cells. 6, 7 Prasad et al identify a significant reduction in homologous recombination (HR) DNA repair genes in the
